The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialStephen Phillips, G.S. Venables, Anna Członkowska et al.|The Lancet|2012Cited by 1.2k
Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burdenJulie Staals, Joanna M. Wardlaw, Stephen Makin et al.|Neurology|2014Cited by 1k
Enlarged Perivascular Spaces on MRI Are a Feature of Cerebral Small Vessel DiseaseFergus Doubal, Joanna M. Wardlaw, Alasdair M. J. MacLullich et al.|Stroke|2010Cited by 913
Is Breakdown of the Blood-Brain Barrier Responsible for Lacunar Stroke, Leukoaraiosis, and Dementia?Joanna M. Wardlaw, John M. Starr, Peter Sandercock et al.|Stroke|2003Cited by 629
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trialMartin Dennis|The Lancet|2018Cited by 285